Return to Work After Hematologic Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study targets adults with hematologic malignancies who have completed induction or consolidation chemotherapy and have not yet returned to work. Participants undergo a specialized return-to-work consultation designed to support resumption of employment. The study aims to see if this intervention improves readiness and likelihood of returning to work, along with related quality-of-life factors. It is conducted at multiple French centers, led by Angers University Hospital. No maintenance therapy is involved, and French-speaking participants who meet criteria are eligible.

Why it matters

Who can join: the full rules

Inclusion Criteria :

* Patient with hematological malignancy controlled after treatment
* Induction/consolidation chemotherapy completed (excluding maintenance therapy)
* Patient aged 18 to 55
* Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy
* Patient who has not yet returned to work since diagnosis of hematological malignancy
* Signed informed consent form

Exclusion Criteria:

* Patient choosing not to return to work
* Patient not affiliated to a social security system
* Patient with legal guardian or legal trustee
* Patient not understanding French
* Patient with severe cognitive impairment at diagnosis, incompatible with the study

Where it's running

• Angers University hospital
  Angers, France Recruiting
• Brest University Hospital, Morvan Site
  Brest, France Recruiting
• Centre Henri Becquerel
  Rouen, France Recruiting
• Tours University Hospital, Bretonneau Site
  Tours, France Recruiting
• Caen University hospital
  Caen, France Not yet recruiting
• Service Hématologie, Cholet Hospital
  Cholet, France Not yet recruiting

Study contacts

• Principal investigator: Jérome PAILLASSA, MD — University Hospital, Angers
• Study coordinator: Jérome PAILLASSA, MD
• Email: Jerome.Paillassa@chu-angers.fr
• Phone: 02 41 35 44 72

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau

  This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.

  Recruiting Affiliated Hospital of Qinghai University · Xining, Qinghai · NCT07205523

• Improving outcomes for stem cell transplant patients using an intervention website

  This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.

  Recruiting at 3 sites Northwestern University · Washington D.C., District of Columbia and 2 other locations · NCT06960993

• Using a NEWS early warning score to prompt ICU admission for adults receiving intensive chemotherapy or stem cell transplant

  This trial tests whether real-time monitoring with the NEWS early warning score and prompt ICU admission (NEWS ≥ 7) helps adults with leukemia, lymphoma, or multiple myeloma who are receiving intensive chemotherapy or a hematopoietic cell transplant.

  Recruiting at 9 sites University Hospital, Angers · Amiens and 9 other locations · NCT06409767

• Evaluating a decision support tool for patients with blood cancers

  This study tests a new tool called PRIME to see if it helps older adults with blood cancers make treatment choices that better match their personal preferences compared to regular care.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06296368

• Improving quality of life for blood cancer patients receiving cellular therapy

  This study is testing a new palliative care program called PEACE to see if it can improve the quality of life for blood cancer patients getting cellular therapy.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05646576

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.